About this trial
Denys-Drash syndrome is a rare genetic disorder of childhood characterized by nephrotic syndrome, nephroblastomas, and genital developmental abnormalities. These children present with rapidly progressive renal failure, leading to kidney transplantation at a median age of 3.6 years. In a study of the French cohort of patients with Denys-Drash syndrome, a high risk of lymphoproliferative syndrome was observed (20%). This frequency is significantly higher than in the general transplant population (4%).
The aim of the study is to evaluate the risk of post-transplant lymphoproliferative disorder following kidney transplantation in patients with Denys-Drash syndrome compared to patients with kidney transplant patients without Denys-Drash syndrome.
Eligibility criteria
Qualifiers
Patient must be a minor at the time of kidney transplantation
Diagnosis of Denys-Drash syndrome (WT1 pathogenic variants in exons 8 or 9) for cases
Controls: minor patient, kidney transplanted at the same center as the case, immediately before and immediately after the case
Kidney transplant recipient on immunosuppressants
Disqualifiers
History of lymphoproliferative disorder prior to transplantation
Other hematopoietic cancer
Other genetic disease with a proven increased risk of lymphoproliferative disorder
Trial design
Treatments tested in this trial
- Collection of data from the patient's medical file
Treatment groups
Sponsors and collaborators
Assistance Publique - Hôpitaux de Paris
Lead sponsor
URC-CIC Paris Descartes Necker Cochin
Collaborator